Genitourinary Cancers

Long-term follow-up found no significant differences in all-cause or disease-related mortality in men with early prostate cancer randomized to either radical prostatectomy or to observation. Surgery led to more adverse events, but less treatment for disease progression.

RNA splicing variants were found to be critical drivers of prostate cancer aggressiveness and therapeutic resistance in African American men.

A urine test of telomerase reverse transcriptase (TERT) was found to be a reliable predictor of recurrence in non–muscle-invasive bladder cancer, according to a new study.

A phase II study has shown that savolitinib is active in a subgroup of patients with papillary renal cell carcinoma with gene amplification or mutations in the MET pathway.

Men with prostate cancer and one additional primary cancer may harbor a mutation in a cancer-predisposing gene, but the majority of these men do not meet criteria for clinical genetic testing.

After extended follow-up, the KEYNOTE-052 study has shown that first-line pembrolizumab offers durable responses and no new safety signals in patients with cisplatin-ineligible advanced urothelial cancer.

The combination of pembrolizumab and the IDO1 inhibitor epacadostat was active and generally well tolerated in patients with urothelial carcinoma.

In this article, we look at both metastatic hormone-sensitive and metastatic castration-resistant disease, and we highlight several of the emerging categories of advanced prostate cancer that have direct implications for patient management.

Despite high rates of toxicity, a first-line tyrosine kinase inhibitor/immunotherapy combination exhibits promising antitumor activity in metastatic renal cell carcinoma.

The FDA has granted approval to pembrolizumab (Keytruda) in the first- and second-line settings for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

A prospective phase III validation study found that AZGP1 has significant prognostic utility as a biomarker in localized prostate cancer.

A study may be able to identify which men with aggressive prostate cancer will benefit from androgen deprivation therapy.

Two new studies presented at the Annual Scientific Meeting of the American Urological Association offer an improved understanding of some genetic underpinnings of prostate cancer.

An interim analysis of the phase III IMvigor211 study found that atezolizumab did not meet its primary endpoint of improving overall survival over chemotherapy in patients with locally advanced or metastatic urothelial cancer.

The FDA has granted accelerated approval to avelumab (Bavencio) for treating locally advanced or metastatic urothelial carcinoma patients whose disease progressed following treatment with platinum-containing chemotherapy.

The FDA has approved durvalumab (Imfinzi) for the treatment of patients with advanced urothelial carcinoma whose disease has progressed after treatment with platinum-containing chemotherapy.

The use of nephron-sparing surgery to treat stage I renal tumors increased between 2009 to 2013 in Australia, showing increased compliance with international guidelines.

A subset of patients with advanced renal cell carcinoma experienced a reduction in tumor size after undergoing postprogression treatment with nivolumab.

The FDA has expanded its approval of atezolizumab (Tecentriq) for the treatment of advanced bladder cancer to include the initial therapy of patients who are not eligible for cisplatin chemotherapy.

From 1983 to 2007, the incidence of renal-malignancy end-stage renal disease has greatly increased, according to the results of a study.

Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.

The use of multi-parametric magnetic resonance imaging could help avoid a repeat prostate biopsy in some men, according to a new study.

In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.

The PD-L1 antibody avelumab was well tolerated and had promising antitumor activity in patients with refractory metastatic urothelial carcinoma.

Maintenance vinflunine yielded longer progression-free survival vs best supportive care in advanced urothelial carcinoma patients after disease control with chemotherapy.

BMI was inversely correlated with serum adiponectin levels in RCC, and low BMI and high adiponectin might be associated with disease aggressiveness and survival in patients with the disease.

The addition of custirsen to docetaxel and prednisone failed to improve overall survival among patients with metastatic castration-resistant prostate cancer in a phase III trial.

Updated results of the ASSURE trial showed that adjuvant sunitinib or sorafenib did not improve disease-free survival among high-risk patients with renal cell carcinoma.

Men who receive testosterone replacement therapy had an increased rate of favorable-risk prostate cancer compared to those who did not use the therapy, and a decreased rate of aggressive prostate cancer.

Event-free survival was not maintained in children and adolescents with intermediate-risk malignant germ cell tumors when cisplatin-based chemotherapy was reduced from four to three cycles and compressed from 5 to 3 days per cycles.